Company Information

CLX Medical, Inc., formerly CLX Investment Company, Inc., was established to engage in on-shore oil and gas exploration, development and production in the continental United States. The Company's oil and gas activities concentrated primarily in Colorado, Kansas, Oklahoma and Wyoming. As of September 30, 2007, the Company operated as a holding company for a controlling interest in one company: Zonda, Inc. On October 15, 2007, the Company entered into a stock purchase agreement with the Oleksiewicz Family Trust (Seller), pursuant to which the Company purchased from the Seller shares of common stock of Zonda, Incorporated. The purchase resulted in an increase in the Company’s total equity position in Zonda, Incorporated to 51%.

Company Contact
Company Contact
Address Sute 203
Murrieta, CA 92563
Telephone (951) 677-6735
Fax (951) 587-8866 http://www.clxmedical.com/

Press Release
CLX Medical, Inc. Releases April 2008 Newsletter Highlighting New Corporate Name and Targeted Acquisition in the Medical Diagnostic Testing Market
Friday 04/25/2008 10:29 AM ET - Market Wire

Related Companies
Symbol Last %Chg
CLXN 0.0011 10.00%

As of 3:59 PM ET 4/29/08
CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today issued its April 2008 investor newsletter, which reviews the company's recent name change to CLX Medical and the announcement of a new targeted acquisition in the medical diagnostic testing market.

A PDF version of the April 2008 newsletter can be viewed on the company's corporate website at http://www.clxinvestments.com/newsletters.php.

The newsletter highlights additional CLX events from the last month, including the identification of and negotiations with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market. The master distributor will provide product support and product packaging control; coordinate sales to other European distributors; distribute products in its own territory; act as the registered EU representative for CE marked products; and assist with the development and implementation of pricing structures.

CLX currently holds a majority interest in Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests, including a rapid point of care test for chlamydia. Zonda's chlamydia product has been distributed in Europe for approximately three years.

Another newsletter article concerns the selection of IIT Research Institute (IITRI) to serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia. A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.

In addition to Zonda's chlamydia product, CLX recently announced that the company has identified a rapid diagnostic device for the medical market that it has targeted for potential acquisition. As additional due diligence and negotiations are undertaken, the company expects to enter into an initial agreement in the form of a letter of intent for the acquisition of the device.

"Each of the events discussed in this month's newsletter are directly tied to the core focus of CLX: to become a leader in the distribution of rapid medical diagnostic testing products," stated Vera Leonard, chief executive officer of Zonda and CLX. "We are very pleased to see progress in virtually every area of the business, and we expect to continue to move forward on all fronts in the coming weeks."

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact:
Gemini Financial Communications, Inc.
A. Beyer
951-677-8073
Email Contact

Chart



This looks like a good starter company. I spoke with IR and he said that they filed their 14C and it was just a name change and no split. He also said that at this point they shouldn't do a split. What do you guys think? I always worry about those splits at the beginning.

Cool I'm thinking 0.0009 may be the buy. It's already up 10%. Maybe we can catch 0.0007 tomorrow if we wait till lunchtime. I watched this on Friday it went to like 0.0015 than it came back down. I put a bid in for 0.0009 at the end of the day today than decided to go with 0.0007, This could pull a BLDV and quadruple in a month with its attention in the PR. I still may put an order in tomorrow just to have this one for the ride.

Good buy right now at 0.0009 May see 0.0007 New news out today. May go in BIG when my funds clear.
CLX Medical, Inc. Announces Letter of Intent for Acquisition of Additional Medical Diagnostic Testing Product
Wednesday 04/30/2008 9:31 AM ET - Market Wire

Related Companies
Symbol Last %Chg
CLXN 0.0009 -18.18%

As of 10:56 AM ET 4/30/08
CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market.

The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.

The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials.

As CLX supports the Zonda product line, it will continue to identify additional innovative products as potential acquisitions and opportunities for distribution relationships for CLX. CLX intends to acquire, license and distribute innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States.

"The letter of intent is an important milestone in the process of acquiring this targeted product," commented Vera Leonard, chief executive officer of Zonda and CLX. "We look forward to reaching the next steps in the process, including the announcement of the name of the product, so we can begin discussing what we see as the significant market potential for this acquisition."

In addition to the U.S. market, the new acquisition may have tremendous potential in Europe, where the Zonda chlamydia product is sold, and in other overseas markets.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact:
Gemini Financial Communications, Inc.
A. Beyer
951-677-8073
Email Contact

This one is on the way to explode just like BLDV?0 Wait till 0.0007?

Nice up today bid 0.001 and ask 0.0011 Should swing back to 0.0009 or 0.0007 This is set to take off the way it keeps jumping needs one more downswing and one more push.

Nice possible $1,000 gain on this tomorrow if it does the same thing. Does somebody have a decent chart? It most likely will. Been doing this since Thurday 0.0009-0.0011. I may go in next price release will go up up up.

Press Release Source: CLX Medical, Inc.


CLX Medical, Inc. Announces Letter of Intent for Acquisition of Additional Medical Diagnostic Testing Product
Wednesday April 30, 9:31 am ET


MURRIETA, CA--(MARKET WIRE)--Apr 30, 2008 -- CLX Medical, Inc. (OTC BB:CLXN.OB - News), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market.
ADVERTISEMENT


The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.

The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials.

As CLX supports the Zonda product line, it will continue to identify additional innovative products as potential acquisitions and opportunities for distribution relationships for CLX. CLX intends to acquire, license and distribute innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States.

"The letter of intent is an important milestone in the process of acquiring this targeted product," commented Vera Leonard, chief executive officer of Zonda and CLX. "We look forward to reaching the next steps in the process, including the announcement of the name of the product, so we can begin discussing what we see as the significant market potential for this acquisition."

In addition to the U.S. market, the new acquisition may have tremendous potential in Europe, where the Zonda chlamydia product is sold, and in other overseas markets.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.



Contact:
Contact:
Gemini Financial Communications, Inc.
A. Beyer
951-677-8073
Email Contact



-------------------------------------------------- ------------------------------
Source: CLX Medical, Inc.

Could have got in at 0.0007 last week I think the 0.0007 days are over now the dips are 0.0009-0.001

Going down may be a good play at 0.0007

Nice dip now at 0.0008 buy ins 0.0007 safe play been doing this the last few weeks Im going in around lunchtime should be 0.0004-0.0005

Ask size 0.0009 down 18% safe play at 0.0007 Nice Oil and Gas Company.

This will definately give it a boost
CLX Medical, Inc. Announces Increasing Interest and Sales of Zonda's Rapid Point of Care Test for Chlamydia
Wednesday 05/07/2008 12:10 PM ET - Market Wire

Related Companies
Symbol Last %Chg
CLXN 0.0010 -9.09%

As of 1:44 PM ET 5/7/08
CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that the company's European distributors have reported an increased interest in diagnostic testing products for chlamydia, which has resulted in increased sales of Zonda Incorporated's rapid point of care test for chlamydia by those distributors.

Distributors in the United Kingdom, Belgium, the Netherlands and Luxemburg have reported the increase over recent months and attribute it to a greater focus on screening for chlamydia by national health organizations in those countries.

The National Chlamydia Screening Programme (NCSP) in the United Kingdom has put an increased focus on the chlamydia epidemic and encourages testing for all sexually active men and women under the age of 25. The program in England was established in 2003 with the objective of controlling chlamydia through the early detection and treatment of asymptomatic infection. As in the United States, chlamydia is now the most commonly reported sexually transmitted infection in the UK.

"Given the growing chlamydia epidemic, it is no surprise that interest in chlamydia screening products, including Zonda's HandiLab-C test for Chlamydia, is increasing in Europe as well as in the United States," commented Vera Leonard, chief executive officer of Zonda and CLX. "Chlamydia is a serious health problem, and we are currently positioning the Zonda chlamydia testing product to serve as an effective and readily available screening rapid point of care device for health care professionals worldwide."

CLX currently holds a majority interest in Zonda, which has developed rapid point of care tests for medical and non-medical markets. Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms and are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets. Zonda's chlamydia product has been distributed in Europe for approximately three years.

CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets. As part of the preparation for clinical trials, a validation study has been commissioned in order to perfect the testing protocol.

The company has also identified and is in negotiations with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market.

The master distributor will provide product support and product packaging control; coordinate sales to other European distributors; distribute products in its own territory; act as the registered EU representative for CE marked products; and assist with the development and implementation of pricing structures.

"Even as we continue through the process of achieving FDA clearance in the United States, we will also work with our selected master distributor to increase the use of the HandiLab-C in the European market," added Ms. Leonard.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc., which has developed rapid point of care tests for medical and non-medical markets, and CLX recently announced a letter of intent to acquire another rapid diagnostic device for the medical market. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact:
Gemini Financial Communications, Inc.
A. Beyer
951-677-8073
Email Contact

Im going in at 0.0007 Calling the broker now lol It has one more push down better get in now

I dont think its an oil company anymore though

Im think I may just put in the order and hope for the bst after my funds clear I dont like playing with unsettled funds becauase then you cant sell them right away its better just to wait. Itll get there tomorrow

Ya I've never traded with unsettled funds.

May be a good play we need the number of trades to hit 400 and 0.0018 this is cruising. By the end of the day this should be playable.